SlideShare a Scribd company logo
An Invitation to Innovation! Louis J DeGennaro, PhD Executive Vice President Chief Scientific Officer The Leukemia & Lymphoma Society
Anyone can get blood cancer In 2009: One million North Americans
The Leukemia & Lymphoma Society Mission: Cure leukemia, lymphoma and myeloma while improving the quality of life for patients and their families.  Advocacy-Patient Services-Research LLS is largest private funder of blood cancer research.  FY2009 Research spend = $72 million ($250 million committed to 400 active projects) Our Vision: blood cancer is eradicated
Goal & Strategy Goal: significantly improve the standard of care Multi-pronged strategy: Raise & deploy capital Fund discovery research in academia Advance development-stage projects to Phase I Alliances with pharma & biotech companies Partner our pipeline Alliances with pharma & biotech Share risk and cost with partners
Research Value Proposition: CML & Gleevec 5yr survival 55% Lives  Saved 90%
The Pathway to Therapies New Therapies!  Research Grant Program Therapy Acceleration Program Discovery Development Commercialize 7 - 10 years ?
Grant Portfolio Overview by Disease $68 MM; 400 active projects $21.2 MM (32.4)% $4.3 MM (6.6)% $8.5 MM (13.0%) $3.6 MM (5.4%) $28 MM (42.7%) Leukemia Lymphoma Myeloma Basic Biology   Gen IM/SCT
CPX Project - AML  Test a panel of 5000 FDA approved, generic drugs CPX kills AML cells in patient samples Our Challenge:  Create an oral formulation – done Regulatory approval for clinical trial – opened in October Accelerate it  –   9 months from concept to trial Toe Nail Fungus Cream
LLS Therapeutic Pipeline Discovery Preclinical Phase I Phase II Phase III Patients Lymphoma - PTLD Acute Leukemia - AML Lymphoma – CLL, FL Lymphoma - CLL Acute Leukemia Lymphoma AML Multiple Trials Novel Drug Delivery Multiple Project Analysis Repurposed drug novel indication Antisense Inhibitor Small Molecule Engineered Immunotherapy Vaccine
Budget FY09 Audited Financials Revenue: $288 million Expenses: $280 million 76% ($213 million) deployed to mission We are not a bank: we raise and deploy these dollars each year
Why donate to, or partner with, LLS? Proven research strategy 400 cutting-edge research projects  A 50-project drug development pipeline Industry-quality approach Competitive intelligence Project management expertise  Smart, non-dilutive capital Access to Key Opinion Leaders A sense of urgency
An Invitation to Innovation! Louis J DeGennaro, PhD Executive Vice President Chief Scientific Officer The Leukemia & Lymphoma Society
Understanding the unmet needs 27 86% 1,300 8,500 HL 70 60% Children 15%   Adults 9,000 12,800 AML 104 69% 19,000 63,000 NHL 56 35% 10,600 20,500 MM 28 90% Children ~50% Adults 1,400 5,800 ALL 55 79% 4500 15,500 CLL 42 89% 500 5,000 CML Drugs in development 5 year overall survival rate Deaths per year New cases per year
Significant Market Opportunity in Blood Cancers Global Sales by Indication (US$  Billions) Current Reported Sales  Followed by Estimates for 2010 (US$ Billions) Per Espicom Business Intelligence 22.728   15.485  7.626   Total 1.265 .995 .493 ALL, MDS, Hodgkin’s 5.585 3.674 1.661 CML 3.814 2.943 .965 Multiple Myeloma .941 .262 .152 AML 5.538 3.937 2.695 NHL 5.585 3.674 1.661 CLL 2012 est. 2009 est. 2005 Indication 1.203 WW sales 4.646   WW sales 7   3.2 .265 US only 2.852 .102 2.6 Velcade Rituxan Sprycel Gleevec
In The Historical Record 1995: Stem Cell IP  > licensed to Athersys 1996: “Hedgehog IP  > partnered with Genentech, compounds in trials 1997: Uses of Inorganic Arsenicals  > marketed as Trisenox by  Cephalon 1998: Second generation Proteosome Inhibitor > licensed to Proteolix , compound in Phase II, myeloma  1998: Vertebrate Apoptosis Gene  > led to formation of Idun, acquired by Pfizer
Portfolio by Target, Mechanism & Modality 0 10 20 30 40 50 60 70 80 Tyrosine Kinase Kinase (Not Tyrosine) Methyl/Acetyl Anti-sense Diagnostic/Biomarker Transcription Cell Cycle Cell Division Apoptosis Small Molecule Antibody Vaccine Immunotherapy Transplant Stem Cell Cell Processes Targeted Therapy Treatment Modality
Portfolio Disease Detail HL NHL CLL, SLL General LY AML CML ALL OM General L Myeloma Gen IM/SCT Basic Biology Dollars Funded in Millions $40 $35 $25 $15 $20 $5 $10 $0 $30 44.9%  34.2% 15%  5.9% %  $ Disease $5 $10 $15 $20 $25 $30 $35 $40
Development Project Portfolio 21 2 1 2 2 3 Scale Up IND Prep Tox Form Dev PK &  ADME Med Chem IND Sub In vivo POP 21 Clinical Trials 10 1 62 Pipeline projects 28 on Watch List  26 Grants in 2009 with potential to move into development ~350  Discovery Projects THERAPIES

More Related Content

What's hot

A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinicalA User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Golden Helix
 
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline WorkflowEvaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Golden Helix
 
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB UpdatesReduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Golden Helix
 
BIO 2010 Partnering with Patients
BIO 2010 Partnering with PatientsBIO 2010 Partnering with Patients
BIO 2010 Partnering with Patients
TRAIN Central Station
 
Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...
Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...
Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...
Golden Helix
 
VSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP Guidelines
VSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP GuidelinesVSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP Guidelines
VSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP Guidelines
Golden Helix
 
Cancer Workflows in VarSeq
Cancer Workflows in VarSeqCancer Workflows in VarSeq
Cancer Workflows in VarSeq
Golden Helix
 
Advanced Report Customization via VSClinical
Advanced Report Customization via VSClinicalAdvanced Report Customization via VSClinical
Advanced Report Customization via VSClinical
Golden Helix
 
Annotation capabilities
Annotation capabilitiesAnnotation capabilities
Annotation capabilities
Golden Helix
 
Evaluating Oncogenicity in VSClinical
Evaluating Oncogenicity in VSClinicalEvaluating Oncogenicity in VSClinical
Evaluating Oncogenicity in VSClinical
Golden Helix
 
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeqPhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
Golden Helix
 

What's hot (11)

A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinicalA User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
 
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline WorkflowEvaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
 
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB UpdatesReduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
 
BIO 2010 Partnering with Patients
BIO 2010 Partnering with PatientsBIO 2010 Partnering with Patients
BIO 2010 Partnering with Patients
 
Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...
Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...
Exome Analysis with VS-CNV and VSClinical: Updated Strategies and Expanded Ca...
 
VSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP Guidelines
VSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP GuidelinesVSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP Guidelines
VSWarehouse Upgrade: Somatic Variant Analysis via VSClinical AMP Guidelines
 
Cancer Workflows in VarSeq
Cancer Workflows in VarSeqCancer Workflows in VarSeq
Cancer Workflows in VarSeq
 
Advanced Report Customization via VSClinical
Advanced Report Customization via VSClinicalAdvanced Report Customization via VSClinical
Advanced Report Customization via VSClinical
 
Annotation capabilities
Annotation capabilitiesAnnotation capabilities
Annotation capabilities
 
Evaluating Oncogenicity in VSClinical
Evaluating Oncogenicity in VSClinicalEvaluating Oncogenicity in VSClinical
Evaluating Oncogenicity in VSClinical
 
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeqPhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
 

Similar to Leukemia Lymphoma Society: An Invitation to Innovation

An Overview of Kancure, LLC
An Overview of Kancure, LLCAn Overview of Kancure, LLC
An Overview of Kancure, LLC
ruchi202
 
Quantum Immunlogics
Quantum ImmunlogicsQuantum Immunlogics
BIO 2010 Partnering with Patients
BIO 2010 Partnering with PatientsBIO 2010 Partnering with Patients
BIO 2010 Partnering with Patients
TRAIN Central Station
 
Islet Investor Presentation Oct 2016 Global Online Growth Conference
Islet Investor Presentation Oct 2016 Global Online Growth ConferenceIslet Investor Presentation Oct 2016 Global Online Growth Conference
Islet Investor Presentation Oct 2016 Global Online Growth Conference
RedChip Companies, Inc.
 
Dendreon.Final
Dendreon.FinalDendreon.Final
Dendreon.Final
sarahmerlen
 
Snti 102013
Snti 102013Snti 102013
CCO_RA2020_Downloadable_1.pptx
CCO_RA2020_Downloadable_1.pptxCCO_RA2020_Downloadable_1.pptx
CCO_RA2020_Downloadable_1.pptx
azzaelnenaey
 
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
Biocat, BioRegion of Catalonia
 
Wesat2203
Wesat2203Wesat2203
Wesat2203
Mohamed Rafique
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Tony Couch
 
Cgix
CgixCgix
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Cirdan
 
BioEurope Presentation, March 2010
BioEurope Presentation, March 2010BioEurope Presentation, March 2010
BioEurope Presentation, March 2010
Advanced Cell Technology, Inc.
 
Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011 Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011
Camp Days
 
Myelin repair open science summit 07.31.10 v2
Myelin repair   open science summit 07.31.10 v2Myelin repair   open science summit 07.31.10 v2
Myelin repair open science summit 07.31.10 v2
Open Science Summit
 
Download Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insightDownload Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insight
KuicK Research
 
Snti red chip jan 2014-reduced
Snti   red chip jan 2014-reducedSnti   red chip jan 2014-reduced
Snti red chip jan 2014-reduced
RedChip Companies, Inc.
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Tony Couch
 
Precysion Glss Presentation Oct Pm2
Precysion  Glss Presentation Oct Pm2Precysion  Glss Presentation Oct Pm2
Precysion Glss Presentation Oct Pm2
pauljmcmahon
 
NeoGenomics Company Overview Presentation 2014-09-12
NeoGenomics Company Overview Presentation 2014-09-12NeoGenomics Company Overview Presentation 2014-09-12
NeoGenomics Company Overview Presentation 2014-09-12
NeoGenomics Laboratory | Cancer Diagnostics
 

Similar to Leukemia Lymphoma Society: An Invitation to Innovation (20)

An Overview of Kancure, LLC
An Overview of Kancure, LLCAn Overview of Kancure, LLC
An Overview of Kancure, LLC
 
Quantum Immunlogics
Quantum ImmunlogicsQuantum Immunlogics
Quantum Immunlogics
 
BIO 2010 Partnering with Patients
BIO 2010 Partnering with PatientsBIO 2010 Partnering with Patients
BIO 2010 Partnering with Patients
 
Islet Investor Presentation Oct 2016 Global Online Growth Conference
Islet Investor Presentation Oct 2016 Global Online Growth ConferenceIslet Investor Presentation Oct 2016 Global Online Growth Conference
Islet Investor Presentation Oct 2016 Global Online Growth Conference
 
Dendreon.Final
Dendreon.FinalDendreon.Final
Dendreon.Final
 
Snti 102013
Snti 102013Snti 102013
Snti 102013
 
CCO_RA2020_Downloadable_1.pptx
CCO_RA2020_Downloadable_1.pptxCCO_RA2020_Downloadable_1.pptx
CCO_RA2020_Downloadable_1.pptx
 
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
 
Wesat2203
Wesat2203Wesat2203
Wesat2203
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
 
Cgix
CgixCgix
Cgix
 
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
 
BioEurope Presentation, March 2010
BioEurope Presentation, March 2010BioEurope Presentation, March 2010
BioEurope Presentation, March 2010
 
Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011 Cancer summitt 2020 buffalo aug 2011
Cancer summitt 2020 buffalo aug 2011
 
Myelin repair open science summit 07.31.10 v2
Myelin repair   open science summit 07.31.10 v2Myelin repair   open science summit 07.31.10 v2
Myelin repair open science summit 07.31.10 v2
 
Download Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insightDownload Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insight
 
Snti red chip jan 2014-reduced
Snti   red chip jan 2014-reducedSnti   red chip jan 2014-reduced
Snti red chip jan 2014-reduced
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
 
Precysion Glss Presentation Oct Pm2
Precysion  Glss Presentation Oct Pm2Precysion  Glss Presentation Oct Pm2
Precysion Glss Presentation Oct Pm2
 
NeoGenomics Company Overview Presentation 2014-09-12
NeoGenomics Company Overview Presentation 2014-09-12NeoGenomics Company Overview Presentation 2014-09-12
NeoGenomics Company Overview Presentation 2014-09-12
 

More from TRAIN Central Station

Valley of Death CAN Briefing Slides
Valley of Death CAN Briefing SlidesValley of Death CAN Briefing Slides
Valley of Death CAN Briefing Slides
TRAIN Central Station
 
Pharma Assets Portal
Pharma Assets PortalPharma Assets Portal
Pharma Assets Portal
TRAIN Central Station
 
Valley of Death Panel Slides at the Partnering for Cures Conference, December...
Valley of Death Panel Slides at the Partnering for Cures Conference, December...Valley of Death Panel Slides at the Partnering for Cures Conference, December...
Valley of Death Panel Slides at the Partnering for Cures Conference, December...
TRAIN Central Station
 
Progeria Research Foundation at Partnering for Cures
Progeria Research Foundation at Partnering for CuresProgeria Research Foundation at Partnering for Cures
Progeria Research Foundation at Partnering for Cures
TRAIN Central Station
 
PATH Malaria Vaccine Initiative
PATH Malaria Vaccine InitiativePATH Malaria Vaccine Initiative
PATH Malaria Vaccine Initiative
TRAIN Central Station
 
Life Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer ResearchLife Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer Research
TRAIN Central Station
 
Susan G. Komen for the Cure Presentation at Partnering for Cures
Susan G. Komen for the Cure Presentation at Partnering for CuresSusan G. Komen for the Cure Presentation at Partnering for Cures
Susan G. Komen for the Cure Presentation at Partnering for Cures
TRAIN Central Station
 
JDRF at the Partnering for Cures Conference
JDRF at the Partnering for Cures ConferenceJDRF at the Partnering for Cures Conference
JDRF at the Partnering for Cures Conference
TRAIN Central Station
 
IAVI's Integrated R&D Program: Accelerating AIDS vaccine development
IAVI's Integrated R&D Program: Accelerating AIDS vaccine developmentIAVI's Integrated R&D Program: Accelerating AIDS vaccine development
IAVI's Integrated R&D Program: Accelerating AIDS vaccine development
TRAIN Central Station
 
FasterCures Presentation at LifeFest 2008
FasterCures Presentation at LifeFest 2008FasterCures Presentation at LifeFest 2008
FasterCures Presentation at LifeFest 2008
TRAIN Central Station
 
FasterCures Presentation: Fostering innovation while delivering treatments an...
FasterCures Presentation: Fostering innovation while delivering treatments an...FasterCures Presentation: Fostering innovation while delivering treatments an...
FasterCures Presentation: Fostering innovation while delivering treatments an...
TRAIN Central Station
 
DNDi: New Drugs for Neglected Diseases; New Hope for Forgotten Patients
DNDi: New Drugs for Neglected Diseases; New Hope for Forgotten PatientsDNDi: New Drugs for Neglected Diseases; New Hope for Forgotten Patients
DNDi: New Drugs for Neglected Diseases; New Hope for Forgotten Patients
TRAIN Central Station
 
TB Alliance: Improving Treatments Against TB
TB Alliance: Improving Treatments Against TBTB Alliance: Improving Treatments Against TB
TB Alliance: Improving Treatments Against TB
TRAIN Central Station
 

More from TRAIN Central Station (13)

Valley of Death CAN Briefing Slides
Valley of Death CAN Briefing SlidesValley of Death CAN Briefing Slides
Valley of Death CAN Briefing Slides
 
Pharma Assets Portal
Pharma Assets PortalPharma Assets Portal
Pharma Assets Portal
 
Valley of Death Panel Slides at the Partnering for Cures Conference, December...
Valley of Death Panel Slides at the Partnering for Cures Conference, December...Valley of Death Panel Slides at the Partnering for Cures Conference, December...
Valley of Death Panel Slides at the Partnering for Cures Conference, December...
 
Progeria Research Foundation at Partnering for Cures
Progeria Research Foundation at Partnering for CuresProgeria Research Foundation at Partnering for Cures
Progeria Research Foundation at Partnering for Cures
 
PATH Malaria Vaccine Initiative
PATH Malaria Vaccine InitiativePATH Malaria Vaccine Initiative
PATH Malaria Vaccine Initiative
 
Life Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer ResearchLife Raft Group: A New Model for Cancer Research
Life Raft Group: A New Model for Cancer Research
 
Susan G. Komen for the Cure Presentation at Partnering for Cures
Susan G. Komen for the Cure Presentation at Partnering for CuresSusan G. Komen for the Cure Presentation at Partnering for Cures
Susan G. Komen for the Cure Presentation at Partnering for Cures
 
JDRF at the Partnering for Cures Conference
JDRF at the Partnering for Cures ConferenceJDRF at the Partnering for Cures Conference
JDRF at the Partnering for Cures Conference
 
IAVI's Integrated R&D Program: Accelerating AIDS vaccine development
IAVI's Integrated R&D Program: Accelerating AIDS vaccine developmentIAVI's Integrated R&D Program: Accelerating AIDS vaccine development
IAVI's Integrated R&D Program: Accelerating AIDS vaccine development
 
FasterCures Presentation at LifeFest 2008
FasterCures Presentation at LifeFest 2008FasterCures Presentation at LifeFest 2008
FasterCures Presentation at LifeFest 2008
 
FasterCures Presentation: Fostering innovation while delivering treatments an...
FasterCures Presentation: Fostering innovation while delivering treatments an...FasterCures Presentation: Fostering innovation while delivering treatments an...
FasterCures Presentation: Fostering innovation while delivering treatments an...
 
DNDi: New Drugs for Neglected Diseases; New Hope for Forgotten Patients
DNDi: New Drugs for Neglected Diseases; New Hope for Forgotten PatientsDNDi: New Drugs for Neglected Diseases; New Hope for Forgotten Patients
DNDi: New Drugs for Neglected Diseases; New Hope for Forgotten Patients
 
TB Alliance: Improving Treatments Against TB
TB Alliance: Improving Treatments Against TBTB Alliance: Improving Treatments Against TB
TB Alliance: Improving Treatments Against TB
 

Recently uploaded

lessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical educationlessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical education
DrJALAGAMTHIRUPATHIR
 
Medical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptxMedical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptx
robel26
 
Recognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptxRecognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptx
FFragrant
 
Hand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing BookHand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing Book
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 
medical law and ethics presentation .ppt
medical law and ethics presentation .pptmedical law and ethics presentation .ppt
medical law and ethics presentation .ppt
PseudoPocket
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
Bright Chipili
 
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdfNUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
MatsikoAlex
 
Text Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT NursingText Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT Nursing
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 
Types of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and CyanosisTypes of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and Cyanosis
MedicoseAcademics
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
drebrahiim
 
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Dr.Nishant Janu
 
Pharmacological Management of Hypertension: New Drugs and Mechanisms
Pharmacological Management of Hypertension: New Drugs and MechanismsPharmacological Management of Hypertension: New Drugs and Mechanisms
Pharmacological Management of Hypertension: New Drugs and Mechanisms
Medwin Publishers
 
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptxPULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
neeti70
 
Respiratory system at glance- Neonatology
Respiratory system at glance- NeonatologyRespiratory system at glance- Neonatology
Respiratory system at glance- Neonatology
Dr. Habibur Rahim
 
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptxNosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
jeearu
 
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.GawadHemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
NephroTube - Dr.Gawad
 
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptxPOTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
souravpaul769171
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Trustlife
 
Interpretation of ECG - Cardiac Arrhythmias
Interpretation of ECG - Cardiac ArrhythmiasInterpretation of ECG - Cardiac Arrhythmias
Interpretation of ECG - Cardiac Arrhythmias
MedicoseAcademics
 
Text book of comprehensive Medical Surgical Nursing
Text book of comprehensive Medical Surgical NursingText book of comprehensive Medical Surgical Nursing
Text book of comprehensive Medical Surgical Nursing
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 

Recently uploaded (20)

lessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical educationlessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical education
 
Medical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptxMedical oncologic management of Colorectal cancer-1-1.pptx
Medical oncologic management of Colorectal cancer-1-1.pptx
 
Recognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptxRecognizing and Managing Bacterial Vaginosis.pptx
Recognizing and Managing Bacterial Vaginosis.pptx
 
Hand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing BookHand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing Book
 
medical law and ethics presentation .ppt
medical law and ethics presentation .pptmedical law and ethics presentation .ppt
medical law and ethics presentation .ppt
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
 
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdfNUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
 
Text Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT NursingText Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT Nursing
 
Types of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and CyanosisTypes of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and Cyanosis
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
 
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
 
Pharmacological Management of Hypertension: New Drugs and Mechanisms
Pharmacological Management of Hypertension: New Drugs and MechanismsPharmacological Management of Hypertension: New Drugs and Mechanisms
Pharmacological Management of Hypertension: New Drugs and Mechanisms
 
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptxPULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
 
Respiratory system at glance- Neonatology
Respiratory system at glance- NeonatologyRespiratory system at glance- Neonatology
Respiratory system at glance- Neonatology
 
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptxNosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
 
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.GawadHemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
 
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptxPOTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
 
Interpretation of ECG - Cardiac Arrhythmias
Interpretation of ECG - Cardiac ArrhythmiasInterpretation of ECG - Cardiac Arrhythmias
Interpretation of ECG - Cardiac Arrhythmias
 
Text book of comprehensive Medical Surgical Nursing
Text book of comprehensive Medical Surgical NursingText book of comprehensive Medical Surgical Nursing
Text book of comprehensive Medical Surgical Nursing
 

Leukemia Lymphoma Society: An Invitation to Innovation

  • 1. An Invitation to Innovation! Louis J DeGennaro, PhD Executive Vice President Chief Scientific Officer The Leukemia & Lymphoma Society
  • 2. Anyone can get blood cancer In 2009: One million North Americans
  • 3. The Leukemia & Lymphoma Society Mission: Cure leukemia, lymphoma and myeloma while improving the quality of life for patients and their families. Advocacy-Patient Services-Research LLS is largest private funder of blood cancer research. FY2009 Research spend = $72 million ($250 million committed to 400 active projects) Our Vision: blood cancer is eradicated
  • 4. Goal & Strategy Goal: significantly improve the standard of care Multi-pronged strategy: Raise & deploy capital Fund discovery research in academia Advance development-stage projects to Phase I Alliances with pharma & biotech companies Partner our pipeline Alliances with pharma & biotech Share risk and cost with partners
  • 5. Research Value Proposition: CML & Gleevec 5yr survival 55% Lives Saved 90%
  • 6. The Pathway to Therapies New Therapies! Research Grant Program Therapy Acceleration Program Discovery Development Commercialize 7 - 10 years ?
  • 7. Grant Portfolio Overview by Disease $68 MM; 400 active projects $21.2 MM (32.4)% $4.3 MM (6.6)% $8.5 MM (13.0%) $3.6 MM (5.4%) $28 MM (42.7%) Leukemia Lymphoma Myeloma Basic Biology Gen IM/SCT
  • 8. CPX Project - AML Test a panel of 5000 FDA approved, generic drugs CPX kills AML cells in patient samples Our Challenge: Create an oral formulation – done Regulatory approval for clinical trial – opened in October Accelerate it – 9 months from concept to trial Toe Nail Fungus Cream
  • 9. LLS Therapeutic Pipeline Discovery Preclinical Phase I Phase II Phase III Patients Lymphoma - PTLD Acute Leukemia - AML Lymphoma – CLL, FL Lymphoma - CLL Acute Leukemia Lymphoma AML Multiple Trials Novel Drug Delivery Multiple Project Analysis Repurposed drug novel indication Antisense Inhibitor Small Molecule Engineered Immunotherapy Vaccine
  • 10. Budget FY09 Audited Financials Revenue: $288 million Expenses: $280 million 76% ($213 million) deployed to mission We are not a bank: we raise and deploy these dollars each year
  • 11. Why donate to, or partner with, LLS? Proven research strategy 400 cutting-edge research projects A 50-project drug development pipeline Industry-quality approach Competitive intelligence Project management expertise Smart, non-dilutive capital Access to Key Opinion Leaders A sense of urgency
  • 12. An Invitation to Innovation! Louis J DeGennaro, PhD Executive Vice President Chief Scientific Officer The Leukemia & Lymphoma Society
  • 13. Understanding the unmet needs 27 86% 1,300 8,500 HL 70 60% Children 15% Adults 9,000 12,800 AML 104 69% 19,000 63,000 NHL 56 35% 10,600 20,500 MM 28 90% Children ~50% Adults 1,400 5,800 ALL 55 79% 4500 15,500 CLL 42 89% 500 5,000 CML Drugs in development 5 year overall survival rate Deaths per year New cases per year
  • 14. Significant Market Opportunity in Blood Cancers Global Sales by Indication (US$ Billions) Current Reported Sales Followed by Estimates for 2010 (US$ Billions) Per Espicom Business Intelligence 22.728 15.485 7.626 Total 1.265 .995 .493 ALL, MDS, Hodgkin’s 5.585 3.674 1.661 CML 3.814 2.943 .965 Multiple Myeloma .941 .262 .152 AML 5.538 3.937 2.695 NHL 5.585 3.674 1.661 CLL 2012 est. 2009 est. 2005 Indication 1.203 WW sales 4.646 WW sales 7 3.2 .265 US only 2.852 .102 2.6 Velcade Rituxan Sprycel Gleevec
  • 15. In The Historical Record 1995: Stem Cell IP > licensed to Athersys 1996: “Hedgehog IP > partnered with Genentech, compounds in trials 1997: Uses of Inorganic Arsenicals > marketed as Trisenox by Cephalon 1998: Second generation Proteosome Inhibitor > licensed to Proteolix , compound in Phase II, myeloma 1998: Vertebrate Apoptosis Gene > led to formation of Idun, acquired by Pfizer
  • 16. Portfolio by Target, Mechanism & Modality 0 10 20 30 40 50 60 70 80 Tyrosine Kinase Kinase (Not Tyrosine) Methyl/Acetyl Anti-sense Diagnostic/Biomarker Transcription Cell Cycle Cell Division Apoptosis Small Molecule Antibody Vaccine Immunotherapy Transplant Stem Cell Cell Processes Targeted Therapy Treatment Modality
  • 17. Portfolio Disease Detail HL NHL CLL, SLL General LY AML CML ALL OM General L Myeloma Gen IM/SCT Basic Biology Dollars Funded in Millions $40 $35 $25 $15 $20 $5 $10 $0 $30 44.9% 34.2% 15% 5.9% % $ Disease $5 $10 $15 $20 $25 $30 $35 $40
  • 18. Development Project Portfolio 21 2 1 2 2 3 Scale Up IND Prep Tox Form Dev PK & ADME Med Chem IND Sub In vivo POP 21 Clinical Trials 10 1 62 Pipeline projects 28 on Watch List 26 Grants in 2009 with potential to move into development ~350 Discovery Projects THERAPIES

Editor's Notes

  1. The following graph is a 5 year survival curve of newly diagnosed CML patients. On standard chemotherapy only 55% survive to the 5 yr mark. However on Gleevec, a targeted therapy, nearly 95% of patients survive. The shift in this graph represents lives saved. And, the Society supported Dr. Brian Druker and others as they developed this revolutionary new “targeted” drug, and continues to support further improvements ~ 20,000 patients diagnosed with chronic phase CML over this period Without Gleevec: expect ~ 4,700 deaths With Gleevec: ~ 700 deaths ~ 4,000 lives saved (and counting)
  2. Discovery = find the root cause of the disease and a potential therapy Development = carrying out the studies required by Regulatory Agencies (FDA, Health Canada) in order to get a new therapy approved/ In addition to discovery and development drugs need to be commercialized in order to get to patients. This is in the hands of the biotech & pharmaceutical industries. LLS now has a comprehensive suite of research programs that covers the discovery (our research grant program) and development (the Therapy Acceleration Program) steps for finding new therapies and is partnering with the pharma industry to get new therapies to the health care providers.
  3. An Academic Concierge Project: The testing of 5000 existing, FDA approved, generic drugs for activity against acute leukemia by an academic investigator receiving one of our grants led to the discovery that a drug used to treat toe nail fungus, CPX, was active in blocking the growth of leukemia cell lines, leukemia in animal (mouse) models and AML cells from patients. Our goal: test the drug in a clinical trial against acute leukemia Process: LLS has assembled a development team to create an oral formulation of the existing product and an application to Health Canada to open a clinical trial Status: The oral formulation is complete. A Clinical Trial Application has been submitted to Health Canada. We expect a positive review and to be able to open a Phase I clinical trial in September. We moved this project forward with remarkable speed: concept to trial in 8 months!
  4. A high level review of the 400 active projects shows that LLS is supporting research across some of the most important areas for the development of targeted therapies, into fundamental cellular processes that regulate cell growth and survival and in virtually every therapeutic modality that applies to treatment of the blood cancers. Now lets focus on the 60 projects that are in the development stage.
  5. The bars and numbers above each step indicate the number of projects at each step in the drug development pathway (small molecule) in the LLS project portfolio. As might be expected, given our large discovery investment and previous neglect of development, most projects are at the earliest steps of this pathway. Given our desire to impact patient outcomes we want to better realize and maximize the value of this pipeline and have instituted the Therapy Acceleration Program to do so.